IDEXX Laboratories beats top-line and bottom-line estimates; updates FY26 outlook
- IDEXX Laboratories press release (IDXX): Q3 Non-GAAP EPS of $3.96 beats by $0.25.
- Revenue of $1.21B (+10.0% Y/Y) beats by $20M.
- Increases 2026 revenue guidance to $4,741 million - $4,767 million (vs. consensus of $4.72B), up $32 million at midpoint, reflecting strong CAG Diagnostics recurring revenue performance.
- Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of 10.3% - 11.0%.
- Raises 2026 EPS outlook to $14.96 - $15.16 (vs. consensus of $14.88), reflecting a $0.25 increase compared to prior guidance midpoint, led by a raised revenue outlook while supporting acquisition impacts.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.